NDC product
Etonogestrel and Ethinyl Estradiol
NDC 0093-7679 · Teva Pharmaceuticals USA, Inc.
Key facts
| Product NDC | 0093-7679 |
|---|---|
| Proprietary name | Etonogestrel and Ethinyl Estradiol |
| Nonproprietary name | Etonogestrel and Ethinyl Estradiol |
| Substances | ETONOGESTREL, ETHINYL ESTRADIOL |
| Dosage form | INSERT, EXTENDED RELEASE |
| Route | VAGINAL |
| Labeler | Teva Pharmaceuticals USA, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA204305 |
| Pharmacologic classes | Estrogen Receptor Agonists [MoA], Estrogen [EPC], Progesterone Congeners [CS], Progestin [EPC] |
| Marketing start | Jan 19, 2021 |
| Marketing end | Jul 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory